A Review of: “Data and Safety Monitoring Committees in Clinical Trials, by J. Herson”

By Gallo Paul  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 6, 2009-11 ,pp. : 1168-1171

Taylor & Francis Ltd

Access to resources Recommend Favorite

Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring

By Muller Patrick Y   Dieterle Frank  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1023-1038

Informa Healthcare

Access to resources Recommend Favorite

A Safety Monitoring Procedure for a Clinical Drug Development Program, with Application to the Assessment of a Novel COX-2 Inhibitor

By Bolland Kim  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 737-749

Taylor & Francis Ltd

Access to resources Recommend Favorite

Regulatory Perspectives on Data Safety Monitoring Boards: Protecting the Integrity of Data

By Hemmings R.   Day S.  

Drug Safety, Vol. 27, Iss. 1, 2004-01 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite

Moxifloxacin Safety: An Analysis of 14 Years of Clinical Data

By Tulkens Paul M.  

Drugs in R&D, Vol. 12, Iss. 2, 2012-06 ,pp. : 71-100

Adis International

Access to resources Recommend Favorite